New Two-Drug attack on tough cancers enters human testing

NCT ID NCT04078295

Ongoing Disease control Sponsor: Eisai Co., Ltd. Source: ClinicalTrials.gov ↗

Summary

This study is testing a new, encapsulated form of a cancer drug (E7389-LF) given together with an existing immunotherapy drug (nivolumab) in people with advanced solid tumors. The first part aims to find a safe and tolerable dose. The second part will see how well the combination works to shrink tumors in specific cancers like stomach, esophageal, and small cell lung cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Eisai Trail Site #16

Sunto-g, Shizuo, Japan
Eisai Trial Site #1

Chuo Ku, Tokyo, Japan
Eisai Trial Site #10

Koto-Ku, Tokyo, Japan
Eisai Trial Site #11

Akashi, Hyōgo, Japan
Eisai Trial Site #12

Kōtoku, Japan
Eisai Trial Site #13

Nagoya, Aichi-ken, Japan
Eisai Trial Site #14

Matsuya, Ehime, Japan
Eisai Trial Site #15

Yokohama, Kanaga, Japan
Eisai Trial Site #17

Suita, Osaka, Japan
Eisai Trial Site #18

Kashiwa, Chiba, Japan
Eisai Trial Site #19

Kitaadachi-gun, Saitama, Japan
Eisai Trial Site #2

Kashiwa, Chiba, Japan
Eisai Trial Site #3

Sendai, Miyagi, Japan
Eisai Trial Site #4

Kurume, Fukuoka, Japan
Eisai Trial Site #5

Osakasa, Osaka, Japan
Eisai Trial Site #6

Chuo Ku, Osaka, Japan
Eisai Trial Site #7

Sakai C, Osaka, Japan
Eisai Trial Site #8

Chuo Ku, Osaka, Japan
Eisai Trial Site #9

Wakayama, Wakaya, Japan

Conditions

Explore the condition pages connected to this study.

SOLID NEOPLASMS